JCI The Journal of Clinical Investigation

Administration of BMP2/7 in utero partially reverses Rubinstein-Taybi syndrome–like skeletal defects induced by *Pdk1* or *Cbp* mutations in mice

Jae-Hyuck Shim, Matthew B. Greenblatt, Anju Singh, Nicholas Brady, Dorothy Hu, Rebecca Drapp, Wataru Ogawa, Masato Kasuga, Tetsuo Noda, Sang-Hwa Yang, Sang-Kyou Lee, Vivienne I. Rebel, Laurie H. Glimcher

J Clin Invest. 2012;122(5):1948-1948. https://doi.org/10.1172/JCI63413.

Corrigendum

Original citation: J. Clin. Invest. 2012;122(1): 91–106. doi:10.1172/JCI59466. Citation for this corrigendum: J. Clin. Invest. 2012;122(5):1948. doi:10.1172/JCI63413. The affiliation for Sang-Hwa Yang and Sang-Kyou Lee was incorrect. In addition, the sentence in Acknowledgments providing the source for Sang-Kyou Lee's research grant was omitted. The correct affiliations list appears above. The omitted sentence is below. This work was supported by National Creative Research Initiatives, a grant from the National Research Foundation of Korea funded by a Korean government grant (2011-0000425 to S.-K. Lee) and the Brain Korea 21 (BK21) Program. The authors regret the error.

Corrigendum

Administration of BMP2/7 in utero partially reverses Rubinstein-Taybi syndrome–like skeletal defects induced by *Pdk1* or *Cbp* mutations in mice

Jae-Hyuck Shim,[1] Matthew B. Greenblatt,[1,2] Anju Singh,[1] Nicholas Brady,[1] Dorothy Hu,[1] Rebecca Drapp,[1] Wataru Ogawa,[3] Masato Kasuga,[4] Tetsuo Noda,[5] Sang-Hwa Yang,[6] Sang-Kyou Lee,[6] Vivienne I. Rebel,[7] and Laurie H. Glimcher[1,2]

[1]Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA. [2]Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. [3]Department of Internal Medicine, Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, Kobe, Japan. [4]Research Institute, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan. [5]Department of Cell Biology, Cancer Institute, Tokyo, Japan. [6]Department of Biotechnology and National Creative Research Initiatives Center for Inflammatory Response Modulation, Yonsei University, Seoul, Republic of Korea. [7]Department of Cellular and Structural Biology, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

Original citation: *J Clin Invest*. 2012;122(1):91–106. doi:10.1172/JCI59466.

Citation for this corrigendum: *J Clin Invest*. 2012;122(5):1948. doi:10.1172/JCI63413.

The affiliation for Sang-Hwa Yang and Sang-Kyou Lee was incorrect. In addition, the sentence in Acknowledgments providing the source for Sang-Kyou Lee's research grant was omitted. The correct affiliations list appears above. The omitted sentence is below.

This work was supported by National Creative Research Initiatives, a grant from the National Research Foundation of Korea funded by a Korean government grant (2011-0000425 to S.-K. Lee) and the Brain Korea 21 (BK21) Program.

The authors regret the errors.

Corrigendum

Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice

Aubrey C. Chan, Stavros G. Drakos, Oscar E. Ruiz, Alexandra C.H. Smith, Christopher C. Gibson, Jing Ling, Samuel F. Passi, Amber N. Stratman, Anastasia Sacharidou, M. Patricia Revelo, Allie H. Grossmann, Nikolaos A. Diakos, George E. Davis, Mark M. Metzstein, Kevin J. Whitehead, and Dean Y. Li

Original citation: *J Clin Invest*. 2011;121(5):1871–1881. doi:10.1172/JCI44393.

Citation for this corrigendum: *J Clin Invest*. 2012;122(5):1948. doi:10.1172/JCI63474.

The control data provided in Figure 7, E, F, and G, were inadvertently provided from incorrectly matched samples. The correct images are below.

The authors regret the error.